Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice by Stirnemann, K et al.
Research article
	 The	Journal	of	Clinical	Investigation      http://www.jci.org  
Sustained activation and tumor targeting  
of NKT cells using a CD1d–anti-HER2–scFv 
fusion protein induce antitumor  
effects in mice
Kathrin Stirnemann,1 Jackeline F. Romero,1 Lucia Baldi,2 Bruno Robert,3 Valérie Cesson,1,4  
Gurdyal S. Besra,5 Maurice Zauderer,6 Florian Wurm,2 Giampietro Corradin,1  
Jean-Pierre Mach,1 H. Robson MacDonald,4 and Alena Donda1
1Department of Biochemistry, University of Lausanne, Epalinges, Switzerland. 2Laboratory of Cellular Biotechnology,  
Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland. 3INSERM U860, CRC Montpellier, University of Montpellier, CRLC Val d’Aurelle,  
Montpellier, France. 4Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland. 5School of Biosciences, 















































































Construction, expression, and purification of recombinant mouse CD1d 










































HER2 binding and biological activity of recombinant CD1d fusion pro-
teins. The sCD1d–anti-HER2 fusion protein specifically bound to 
Figure 
Design, production, and purification of recombinant 
CD1d molecules. (A) Design of the genetic fusions of 
mouse β2m with the sCD1d and the single chain of the 
murine anti-HER2 antibody 4D5 (4D5 scFv). DNA frag-
ments were produced by PCR using primers, including 
sequences for flexible glycine-serine rich linkers (G10S3 
and G3S3). A His-tag (His)6 was added at the C-termi-
nus for Ni-NTA purification. (B) sCD1d and sCD1d–anti-
HER2 fusion proteins after production in HEK293EBNA 
cells. Shown are 10% SDS-PAGE after purification of 
the proteins by Ni-NTA chromatography (upper panel) 
and FPLC Sephacryl S100 profiles after loading with 
αGalCer (lower panels). β2m-L, leader sequence of 
β2m; α1-3, extracellular domains of CD1d; M, molecular 
weight markers.
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The αGalCer/sCD1d–anti-HER2 fusion protein bound on tumor cells pre-



































Binding and biological activity of recombinant CD1d molecules. (A) Binding of the sCD1d–anti-HER2 protein to HER2-expressing target cells, 
and recognition by FITC-labeled anti-CD1d. HER2-positive target cells (B16-HER2 and SKBR3) are recognized while HER2-negative LoVo 
cells are not. (B) Titration of the binding of the sCD1d–anti-HER2 scFv protein or the full anti-HER2 antibody Herceptin to B16-HER2 cells. 
Detection was performed using anti-CD1d–FITC and anti-human IgG FITC, respectively. (C) In vivo bioactivity of αGalCer-loaded sCD1d and 
sCD1d–anti-HER2, shown by the transient disappearance of liver iNKT cells secondary to the activation-induced downmodulation of the invari-
ant T cell receptor. Liver lymphocytes were analyzed for numbers of iNKT cells 20 hours after i.p. injection of PBS (control) and 5 μg αGalCer, 
20 μg unloaded or αGalCer-loaded sCD1d, 40 μg unloaded or αGalCer-loaded sCD1d–anti-HER2 fusion. Detection by FACS using PE-labeled 
αGalCer/CD1d-tetramer and FITC-labeled anti-CD3. Results are expressed in percent of iNKT cells from total liver lymphocytes.
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Delayed systemic treatment with the αGalCer/sCD1d–anti-HER2 leads 









In  contrast,  systemic  treat-
ment with equimolar amounts 
of the αGalCer/sCD1d–anti-
HER2  fusion  protein,  when 





















































In vivo antitumor activity and HER2 dependency in a precoating experiment. (A) Comparison of 2 different 
read-out methods for counting lung tumor colonies induced by the i.v. injection of B16 F10 melanoma cells 
in 2 representative mice (1 and 2): counting of nodules (upper panels) versus the use of ImageJ k-means 
clustering algorithm program to integrate the black surface of melanin-loaded nodules and to express the 
result as percent of black surface over total lung surface (lower panels). Original magnification, ×6.3. (B 
and C) Precoating experiment. B16-HER2 (B) and B16 wt cells (C) were precoated for 1 h with equimolar 
amounts of αGalCer (0.4 μg/ml), αGalCer/sCD1d–anti-HER2 fusion (40 μg/ml), or Herceptin (10 μg/ml). 
With or without a previous wash, cells were injected i.v. in C57BL/6 mice. Lung metastases were analyzed 3 
weeks after graft as described in A. Results are expressed as percent of black surface of total lung surface 
and represent the mean ± SD of 5 mice per group of 3 independent experiments. *P < 0.005 compared 
with PBS control.
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iNKT cells are required for the antitumor effect of the 
αGalCer/sCD1d–anti-HER2 fusion protein.  To  prove 
the essential role of activated iNKT cells in the anti-












In vivo antitumor activity in systemic treatments. (A) Mice 
were grafted i.v. with 700,000 B16-HER2 cells and i.v. 
treatment was started 48 hours later. Mice were injected 
5 times i.v. every 3–4 days (arrows) with either PBS (con-
trol), equimolar amounts of αGalCer (0.4 μg), or αGalCer-
loaded sCD1d–anti-HER2 fusion (40 μg). Mice were ana-
lyzed after 3 weeks and results are shown as pictures of 
tumors-invaded lungs (1 representative lung per group; 
original magnification, ×6.3), and in the graph expressed as 
percent of lung surface invaded by melanin-loaded tumor 
nodules. Results represent the mean ± SD of 5 mice per 
group of 2 independent experiments. **P < 0.005 versus 
control; *P < 0.04 versus αGalCer. (B) Mice were grafted 
as above, and treatment was started 6 days after with the 
same protocol as in A including treatment with sCD1d 
(25 μg). Lung nodules were analyzed after 2 weeks. 
Results represent the mean ± SD of 6 mice per group of 
2 independent experiments. ***P = 0.0006 versus control; 
**P < 0.004 versus αGalCer; *P < 0.02 versus sCD1d. (C) 
Mice were grafted s.c. on the right flank with 700,000 B16-
HER2 cells and i.v. treatment as in B was started 7 days 
later, when all tumors were palpable. Additional groups 
treated with 4D5 alone (80 μg) or the combination of 
4D5 + sCD1d (80 + 25 μg) were included. Results 
expressed as the mean tumor size in mm3 ± SD measured 
at the end of the treatment (day 18) of 4 mice per group. 
Statistical significance of αGalCer/sCD1d–anti-HER2–
treated group was of *P < 0.05 versus all other groups.
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iNKT cells remain responsive to repeated injections of recombinant 





















iNKT cells activated by recombinant αGalCer/sCD1d proteins retain 

































iNKT cells are required for the antitumor effect and are characterized by 
a sustained activation with TH1 bias. (A) The antitumor activity is lost 
in the absence of iNKT cells. C57BL/6 or CD1d–/– mice were grafted 
on the left flank with 700,000 B16-HER2 cells, and systemic treatment 
with the αGalCer/sCD1d–anti-HER2 was started 2 days later (40 μg/
i.v. injection every 3 days). For each mouse strain, a group was left 
untreated. Results represent the kinetic of s.c. tumor growth (in mm3) 
as the mean ± SD of 4 mice per group. (B) Ex vivo IFNγ production by 
liver iNKT cells after several injections of αGalCer/sCD1d–anti-HER2 
fusion. Liver lymphocytes were isolated 20 minutes after the sixth 
injection of PBS (control), αGalCer, or sCD1d–anti-HER2 protein, and 
cultured for 1 h. Cells were stained with anti-NK1.1–PE and anti-CD3–
FITC, and intracellularly with anti-IFNγ–APC. Graph shows percent 
of IFNγ-producing iNKT (gated on NK1.1+ CD3+ cells). (C) Sustained 
IFNγ production by liver iNKT cells after several i.v. injections as indi-
cated, followed by in vitro rechallenge with the same stimuli as in vivo. 
Liver lymphocytes were isolated 3 days after the fifth injection and 
restimulated in vitro for 6 hours. Naive mice were tested with αGalCer 
or αGalCer/sCD1d–anti-HER2. Cells were stained as described in 
B and results are expressed as fold increase of IFNγ-producing liver 
iNKT cells compared with the nonstimulated iNKT fraction derived 
from the same mouse. White bar, no in vitro stimulation; gray bar, in 
vitro αGalCer; black bar, in vitro sCD1d–anti-HER2. Results show the 
mean ± SD of 3 different experiments. *P < 0.03, **P < 0.005.
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Repeated injections of recombinant αGalCer/sCD1d proteins leads to 











Systemic injection of the αGalCer/sCD1d–anti-HER2 protein leads 
to an accumulation of iNKT, NK, and T cells at the tumor site and to a 










Activated iNKT cells retain their capacity to transactivate NK cells and promote DC maturation. Production of IFNγ by NK cells in the same mice 
analyzed in Figure 5, ex vivo 20 min after an i.v. injection (A) or after in vitro rechallenge (B). NK population was gated on NK1.1 single posi-
tive cells. (A) Results are expressed as percent of IFNγ-producing NK cells. (B) Same legend as in Figure 5B. *P < 0.05; **P < 0.0006. (C) The 
antitumor activity is in great part lost after NK cell depletion. Three groups of mice were grafted s.c. with 700,000 B16-HER2 cells, and 2 groups 
were treated with the αGalCer/sCD1d–anti-HER2 fusion 7 days later when tumors were palpable. For NK cell depletion, 1 of these groups 
was repeatedly i.p. injected with anti-asialo–GM1 antibodies during the whole treatment with the αGalCer/sCD1d–anti-HER2 protein. Results 
represent the kinetic of s.c. tumor growth (in mm3) as the mean ± SD of 4 mice per group. (D) Induction of DC maturation by αGalCer/sCD1d-
activated iNKT cells. Splenocytes were isolated 16 hours after the third i.v. injection of PBS (control), equimolar amounts of αGalCer (0.4 μg), 
or αGalCer-loaded sCD1d (25 μg). DCs were sorted with anti-CD11c magnetic beads and stained with anti-CD11c–FITC and either biotinylated 
with anti-CD80, anti-CD86, or anti-CD40 antibodies followed by Streptavidin-PE. Results show the 3 activation markers on gated CD11c-positive 
cells, and numbers indicate the percent of cells with upregulated marker.
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importantly,  when  targeted  to  the 
tumor site by the genetic fusion of an 
anti-HER2 scFv antibody  fragment 
to  the carboxy  terminus of  sCD1d, 
delayed systemic treatment of mice 
allowed a potent inhibition of lung 





















































Recombinant αGalCer/sCD1d proteins induce a higher frequency of iNKT cells. (A) iNKT cell expan-
sion after several injections of recombinant αGalCer-loaded CD1d molecules. Mice from systemic 
treatments (Figure 4) were bled after the third injection, and iNKT cells were stained in PBMCs using 
CD1d-tetramer-PE and anti-CD3–FITC. Dot plots of 1 representative mouse per group are shown, 
and numbers indicate percent of iNKT cells in total PBMCs. (B) Percent of iNKT cells in 4 individual 
mice per group including mean value. 
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The αGalCer/sCD1d–anti-HER2 fusion protein redirects iNKT, NK, and T cells to HER2-expressing lung tumors and specifically localizes at 
the tumor site. To study tumor targeting, mice were grafted with 700,000 B16-HER2 cells i.v., and systemic treatment, as described in Figure 
4, was started 10 days after the tumor graft. For BrdU-incorporation, mice were injected i.p. with 1 mg BrdU on day 10, and BrdU was added to 
the drinking water throughout the whole experiment. Two days after the third injection, mice were sacrificed, lymphocytes were isolated from 
lungs, spleen, and PBMCs and stained with anti-NK1.1–PE, anti-CD3–FITC, and anti-BrdU–APC. Proliferation of iNKT, NK, and CD3 T cells is 
shown as percent of BrdU-positive cells in the respective population. (A) Dot plots with numbers indicating the percent of BrdU-positive iNKT, 
NK, and T cells isolated from lung tissue and (B) graphs of BrdU-incorporation in iNKT, NK, and CD3 T cells from lungs, spleen, and PBMC 
expressed as fold increase of BrdU-positive cells compared with control group. (C) Biodistribution study with radiolabeled sCD1d molecules. 
Mice were grafted s.c. on each flank with 1 × 106 of either B16-HER2 or B16 wt cells. On day 8, 2 groups of mice were injected with equimolar 
amounts of either 125I-labeled αGalCer/sCD1d or αGalCer/sCD1d–anti-HER2. Twenty-four hours later, mice were sacrificed and radioactivity 
was measured in tumors and normal tissues. Results are expressed as percent of injected dose per gram of tissue. Mean ± SD of 3 mice per 
group. *P < 0.05 for αGalCer/sCD1d–anti-HER2 in B16-HER2 tumors versus B16 wt tumors; **P < 0.02 for αGalCer/sCD1d–anti-HER2 versus 
αGalCer/sCD1d in B16-HER2 tumors.
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T cells: development,  specificity,  and  function. 
Annu. Rev. Immunol. 15:535–562.













































cells  in patients with  advanced  and  recurrent 
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